Westfield Capital Boosts Bio-Rad Laboratories Holdings

Investment firm increases stake in medical research company by 11.5% in Q3

Feb. 27, 2026 at 1:27pm

Got story updates? Submit your updates here. ›

Westfield Capital Management Co. LP, an institutional investor, increased its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 11.5% during the third quarter of 2025, according to a recent SEC filing. Westfield Capital now owns approximately 0.57% of Bio-Rad Laboratories, a medical research company.

Why it matters

Bio-Rad Laboratories is a prominent player in the medical research industry, providing instruments, reagents and other products for applications like protein analysis, cell biology, and molecular diagnostics. Westfield Capital's increased stake signals confidence in the company's growth potential and future performance.

The details

According to the SEC filing, Westfield Capital Management added 16,019 shares of Bio-Rad Laboratories during Q3 2025, bringing its total holdings to 155,524 shares. This represents approximately 0.57% ownership of the company. Bio-Rad Laboratories has a market capitalization of $7.43 billion and its stock trades on the New York Stock Exchange.

  • Westfield Capital Management increased its Bio-Rad Laboratories holdings during the 3rd quarter of 2025.
  • The SEC filing detailing the transaction was published on February 27, 2026.

The players

Westfield Capital Management Co. LP

An institutional investment firm that manages over $25 billion in assets.

Bio-Rad Laboratories, Inc.

A global provider of life science research and clinical diagnostic products, headquartered in Hercules, California.

Got photos? Submit your photos here. ›

The takeaway

Westfield Capital's increased stake in Bio-Rad Laboratories suggests the investment firm sees strong growth potential in the medical research company, which could signal positive momentum for Bio-Rad's business and stock performance going forward.